v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Expenses:    
Research and development $ 57,621 $ 258,876
General and administrative 1,247,077 1,885,695
Total Operating Expenses 1,304,698 2,144,571
Loss From Operations (1,304,698) (2,144,571)
Other (Income) Expense:    
Interest expense 132,512 119,559
Fair value option loss on convertible notes 344,000
Change in fair value of warrant liabilities (16,000)
Change in fair value of equity payable 28,171 (7,200)
Net Loss $ (1,793,381) $ (2,256,930)
Net Loss Per Share    
Basic $ (0.22) $ (0.73)
Diluted $ (0.22) $ (0.73)
Weighted Average Number of Common Shares Outstanding    
Basic 8,095,921 3,106,928
Diluted 8,095,921 3,106,928